Egypt - English - EDA (Egyptian Drug Authority)

ema pharm-egypt - coated tablet - 200 mg

New Zealand - English - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - alpha1-proteinase inhibitor 1000mg (human) - powder for infusion - 1000 mg - active: alpha1-proteinase inhibitor 1000mg (human) excipient: hydrochloric acid mannitol monobasic sodium phosphate monohydrate sodium chloride sodium hydroxide water for injection - zemaira is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe a1-pi deficiency (a1-pi < 11 µm) and progressive lung disease. patients are to be under optimal pharmacologic and non-pharmacologic treatment.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pahang pharmacy sdn. bhd. - esomeprazole magnesium dihydrate -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pahang pharmacy sdn. bhd. - esomeprazole magnesium dihydrate -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

synerrv sdn bhd - irbesartan -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

synerrv sdn bhd - irbesartan -

Canada - English - Health Canada

teva canada limited - fremanezumab - solution - 225mg - fremanezumab 225mg - calcitonin-gene-related peptide (cgrp) antagonists

Canada - English - Health Canada

teva canada limited - fremanezumab - solution - 225mg - fremanezumab 225mg - calcitonin-gene-related peptide (cgrp) antagonists

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - alpha-1-proteinase inhibitor, quantity: 1000 mg - solution - excipient ingredients: - zemaira is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe a1-pi deficiency (a1-pi less than 11 micromolar) and progressive lung disease. patients are to be under optimal pharmacologic and non-pharmacologic treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

bausch & lomb australia pty ltd - loteprednol etabonate, quantity: 5 mg/ml - eye drops, suspension - excipient ingredients: tyloxapol; povidone; benzalkonium chloride; glycerol; sodium hydroxide; hydrochloric acid; purified water; disodium edetate - lotemax is indicated for:,? treatment of post-operative inflammation following cataract surgery,? treatment of steroid responsive inflammatory conditions of contact lens associated giant papillary conjunctivitis (gpc).